5.25
-0.64
(-10.87%)
At close: April 11 at 4:00:01 PM EDT
5.25
0.00
(0.00%)
After hours: April 11 at 4:05:10 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.95 | -1.11 | -3.6 | -2.25 |
| Low Estimate | -1.07 | -1.32 | -4.25 | -3.08 |
| High Estimate | -0.83 | -0.97 | -3.2 | -1.63 |
| Year Ago EPS | -4 | -6.75 | -12.17 | -3.6 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -4.25 | -4.12 | -7.12 | -2.36 |
| EPS Actual | -4 | -6.75 | -4.54 | -- |
| Difference | 0.25 | -2.63 | 2.59 | -- |
| Surprise % | 5.88% | -63.64% | 36.28% | -- |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.95 | -1.11 | -3.6 | -2.25 |
| 7 Days Ago | -0.76 | -1.23 | -3.56 | -2.57 |
| 30 Days Ago | -0.76 | -1.23 | -3.56 | -2.57 |
| 60 Days Ago | -0.76 | -1.23 | -3.56 | -2.57 |
| 90 Days Ago | 0 | 0 | -3.81 | -2.17 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | 1 | 1 | 2 | 1 |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| FBRX | 76.25% | 83.56% | 70.45% | 37.44% |
| S&P 500 | 6.43% | 6.13% | 9.43% | 14.26% |
Upgrades & Downgrades
| Maintains | Chardan Capital: Buy to Buy | 4/1/2025 |
| Initiated | TD Cowen: Buy | 1/21/2025 |
| Maintains | Chardan Capital: Buy to Buy | 12/4/2024 |
| Maintains | Chardan Capital: Buy to Buy | 11/15/2024 |
| Maintains | Chardan Capital: Buy to Buy | 8/19/2024 |
| Initiated | Brookline Capital: Buy | 5/30/2024 |
Related Tickers
SRZN Surrozen, Inc.
9.00
0.00%
ITOS iTeos Therapeutics, Inc.
5.65
+9.07%
COEP Coeptis Therapeutics Holdings, Inc.
9.40
0.00%
FENC Fennec Pharmaceuticals Inc.
5.01
0.00%
PVLA Palvella Therapeutics, Inc.
21.76
+9.51%
VRDN Viridian Therapeutics, Inc.
12.02
+5.35%
MNPR Monopar Therapeutics Inc.
34.89
+9.48%
ENGN enGene Holdings Inc.
4.0000
0.00%
PRAX Praxis Precision Medicines, Inc.
29.74
+4.46%
XNCR Xencor, Inc.
8.54
+7.83%